
Superpower peptides available for pre-order. Get first access.

Peptide science
What are the side effects of ARA-290?
ARA-290 side effects in Phase II trials were mostly mild, but serious events occurred and long-term safety is unknown. See what trials found.
Quick answer
ARA-290 side effects in Phase II trials were mostly mild. In the 64-person sarcoidosis trial, 3 of 46 people on ARA-290 had a serious event. In the type 2 diabetes trial, researchers judged 2 of 4 serious events possibly related. Red cell, platelet, and white cell counts held steady over 28 days. Trials lasted 12 weeks at most, so long-term safety is unknown. ARA-290 is not FDA-approved.
- Published
- November 11, 2026
- Last updated
- November 11, 2026
ARA-290 side effects were mostly mild in small trials
ARA-290 side effects recorded in small Phase II trials were mostly mild. Serious adverse events also occurred, and researchers judged two of them possibly related to ARA-2901. The peptide's long-term safety is unknown. ARA-290 also goes by the name cibinetide2. Superpower does not offer or sell ARA-290.
ARA-290's safety record comes from a handful of short trials in different patient groups.
Side effects recorded in ARA-290 Phase II trials
Most adverse events graded in ARA-290 Phase II trials were mild1. The effects reported most often included headache, fatigue, and nausea3. Every study was small and short, and most were ARA-290 neuropathy trials in people with nerve damage from sarcoidosis (an inflammatory disease) or diabetes.
| Trial population | Participants | Study length | Adverse events recorded |
| Sarcoidosis neuropathy, pilot | 22 (12 ARA-290, 10 placebo) | 4 weeks | No safety concerns on clinical or lab checks4 |
| Sarcoidosis or type 2 diabetes, open-label | 20, no placebo | 1 week | No relevant adverse events noted5 |
| Sarcoidosis neuropathy | 38 | 28 days | No significant adverse effects reported5 |
| Sarcoidosis neuropathy, Phase 2b | 64 (16 per group, 3 doses and placebo) | 28 days, 84-day follow-up | Non-serious events in 37 of 46 on ARA-2903 and 12 of 16 on placebo |
| Type 2 diabetes with neuropathy | 49 (48 analyzed) | 28 days, 1-month follow-up | 54 mild, 9 moderate, and 1 severe event1 on ARA-290; 61 mild and 5 moderate on placebo |
| Diabetic macular edema, open-label | 9, no placebo | 12 weeks | Every participant had at least 1 event6, none serious |
Serious adverse events occurred in two ARA-290 trials. In the 64-person sarcoidosis trial7, 3 of 46 people on ARA-2903 had a serious event, against none of 16 on placebo. The trial record does not say whether ARA-290 caused them. The type 2 diabetes trial recorded four serious events in the ARA-290 group1, and researchers judged two possibly related. Among more than 200 people given ARA-2906, one person with a history of depression reported suicidal thoughts during use.
ARA-290 was engineered from part of erythropoietin8, the hormone that drives red blood cell production. In cell and animal studies, the peptide did not stimulate red blood cell formation9. In the 28-day type 2 diabetes trial, red cell, platelet, and white cell counts showed no clinically significant changes1. Those checks cover weeks of use, leaving longer use an open question.
The long-term safety of ARA-290 remains unknown
ARA-290's long-term safety is unknown, because published trials lasted weeks and had short follow-up. Researchers have called for trials with longer dosing and follow-up5. The longest dosing period, 12 weeks, came from a nine-person pilot with no control group and short follow-up6. Those gaps concern the compound studied in trials, and products sold outside trials add questions of their own.
Unregulated ARA-290 products carry identity and purity risks
ARA-290 sold online is made outside drug-quality oversight, so its identity, purity, and dose go unverified10. Unregulated peptides carry risks of contamination, manufacturing impurities, and inaccurate dosing11. As of November 2026, ARA-290 is not FDA-approved. FDA lists cibinetide among bulk substances nominated for compounding without adequate support12.
Sellers often label peptides "for research use only."10 A certificate of analysis may not show what a vial contains10. Peptide drugs bought from illegal online pharmacies tested at purity as low as 5%13. Some also contained toxic metals, including lead and arsenic. Another test purchase found bacterial endotoxin (a toxin from bacterial cell walls) in all three injectable peptide vials14 delivered. Peptides made without pharmaceutical quality control can also carry missing or extra amino acids15, changing their sequence. Beyond these product risks, ARA-290 has little or no safety data for some groups of people.
ARA-290 has little or no safety data for excluded groups
ARA-290 trials excluded several groups of people3, so little or no safety data exist for them. For some of these groups, ARA-290's proposed biology also raises theoretical concerns.
- Current or recent cancer: trial protocols excluded people with cancer diagnosed or treated in the past five years16. Erythropoietin's tissue-protective signaling, which ARA-290 targets, helps cells resist dying17. In cancer studies of erythropoietin drugs, the effect on tumors remained uncertain18. The concern is theoretical and comes from erythropoietin research.
- Pregnancy or breastfeeding: ARA-290 studies, including one in healthy volunteers19, excluded people who were pregnant or breastfeeding20, so no data exist.
- Reduced kidney function: one diabetes trial protocol excluded people with impaired kidney function16, so data are scarce. In the type 2 diabetes trial, one participant's borderline kidney impairment worsened slightly1, and ARA-290 was stopped.
Until larger and longer ARA-290 trials report, these groups have little or no data to weigh risk against.
Where can I learn about peptides?
Superpower’s peptide library is written and fact-checked by a team of health journalists and licensed clinicians. Weighing an investigational peptide's side effects starts with separating trial data from product risks.
The science behind peptides explains how short chains like ARA-290 are made and tested.
IMPORTANT SAFETY INFORMATION
ARA-290 (cibinetide) is NOT FDA-approved for any indication. It is not legally marketed for human use. Superpower Health does not prescribe, sell, compound, or facilitate access to ARA-290. This page is provided for educational purposes only and does not constitute medical advice.
Clinical safety data come from small Phase II trials lasting 12 weeks at most. Most reported adverse events were mild, most often headache, fatigue, and nausea. Serious adverse events occurred in two trials, and researchers judged two events in the type 2 diabetes trial possibly related to ARA-290. Red cell, platelet, and white cell counts showed no clinically significant changes over 28 days in that trial. Longer-term safety has not been characterized.
ARA-290 should not be used by anyone outside an IRB-approved clinical research study. No approved label exists, so no formal contraindications exist. Populations of particular concern, based on trial exclusions and the compound's proposed mechanism, include: individuals with current or recent cancer (theoretical cell-survival signaling effects); pregnant or breastfeeding individuals (excluded from studies, so no data exist); and individuals with reduced kidney function (excluded from at least one trial, and one participant's pre-existing kidney impairment worsened during dosing). These are illustrative concerns, not a contraindication checklist.
Products sold online as ARA-290 or cibinetide are unregulated and often labeled "for research use only." Their identity, purity, and dosing have not been verified by the FDA or any independent regulatory authority. There is no legal pharmaceutical-grade source for ARA-290 in the United States.
This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to ARA-290. ARA-290 is not FDA-approved for human use. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.